PHP86 Treatment Costs In Primary And Secondary Healthcare In Finland  by Purmonen, T et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A529
remain at year 2013 level, and these were then combined with official population 
forecasts. Results: Altogether 160,952 individuals (81% of all inhabitants) had at 
least one healthcare contact during the follow up. Primary and secondary healthcare 
services had been used by 155,631 and 59,589 patients, respectively. The average 
annual cost per patient was 1,853€ . The average cost in primary and secondary 
healthcare was 808€ and 2,895€ , respectively. Variation was wide across the dif-
ferent ages (Primary healthcare, range: 346€ –5,645€ ; Secondary healthcare, range: 
1,282€ –4,474€ ). Due to aging of the population only, according to the future projec-
tions, in the year 2025, the total primary healthcare costs are 21% and secondary 
healthcare costs 14% higher than in 2013. ConClusions: With respect to costs, 
aging of the population affects primary healthcare more than specialized health-
care. Thus, the healthcare utilization should be regarded as one entity taking into 
account both primary and secondary healthcare services. If the overall treatment 
process, from primary care to secondary care and sometimes back to primary care, 
is not taken in to account, this will lead to suboptimal decision making.
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objeCtives: To describe health service utilization (HSU) patterns of dengue cases 
by age, severity of illness, and healthcare sector, in Brazil during an epidemic den-
gue transmission period. Methods: A multicenter cohort study was conducted 
in 2012-2013 at four Brazilian endemic regions. Patients were ascertained in units 
and hospitals from both public and private sectors. Data collection was performed 
by interviewing 15-20 days after the onset of symptoms and review of medical 
records of hospitalized patients. HSU specific information included: access and 
type of healthcare service, type and quantity of diagnostic, laboratory and imag-
ing tests, medical procedures, and medications. Results: A total of 2,035 (91.5%) 
dengue cases were recruited to our study: 1,657 (81.4%) were outpatients and 378 
(18.6%) inpatients; 1,361 (66.9%) were assisted at public and 674 (33.1%) at private 
sector; 398 (19.6%) children and 1,635 (80.4%) adults. Public sector has higher medi-
cal visits average which ranged from 1.2 in Teresina (Northeast) to 4.2 in Goiânia 
(Midwest) for outpatients, and from 3.2 in Goiânia to 5.0 in Teresina for inpatients. 
Hospital length of stay varied from 3-4 days. Full blood count was carried out in 
80% of cases; in 75% of adults, in both outpatients and inpatients. X-ray tests were 
performed in 8.2% of outpatients and 26.2% of inpatients, with most adults (75.0%). 
Frequently outpatients and inpatients reported medication use, 71.0% and 65.9% 
respectively, specially at public sector (75.0%). ConClusions: Our results show 
that HSU patterns of dengue cases have extensive variations regarding healthcare 
sector, severity of illness, and different regions of Brazil. The HSU could be affected 
by dengue clinical guidelines utilized in healthcare service.
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objeCtives: In Germany parallel imports does not only exist due to economic 
reasons like arbitrage principle, but due to special legislative support. According to 
law, pharmacies have to fulfil a predetermined import quota to achieve a certain 
efficiency reserve which should help generating higher savings for the statutory 
health insurance. Prices of imports are only cost efficient if they are fulfilling a 
minimum price difference which is 15% or 15 Euro below the prices of originals. 
The objective is to determine whether imports are price efficient and if they obtain 
the legally implemented savings. Methods: This analysis evaluates data from 
IMS-Database which covers all redeemed GKV receipts. Imports were identified by 
pharmacy number (PZN). Afterwards they were ordered by Anatomical Therapeutic 
Chemical (ATC)-Coding and listed separately for GKV-sales and market share. 
Market share was identified by units sold, sales on basis of manufactures price. 
Prices were taken from a public price list (Lauer-Taxe). For overall savings publi-
cized data were used (Arzneimittel-Atlas). Evaluation period was 2013. Results: 
Imports are focussing on special therapeutics, mainly covering Neurologics (ATC1 
“N”) and Immunsuppressiva (ATC1 “L”). Both indications received a market share 
of 38.7% with sales of 2.5 bio. euro. By looking at the top 5 imports with highest 
sales cost efficient prices according to legal rule are only apparent in 3 of 5 cases 
(absolute rating) and 1 of 5 cases (relative rating). In general, prices of imports are 
oriented to prices of originals and sometimes even excess them. Annual savings 
are 63.5 mio. euro. ConClusions: Imports are focussing on special therapeutic 
areas which mainly lead to high margins for importers. Prices are not efficiently 
according to legal rule so that the expected savings does not result. Therefore 
the existing regulation of import quota should be disestablished. Imports should 
regulate themselves by the competition of the market but without additional 
support by legislation.
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formulary non-adherence and 8 (38.1%) for early refill detection. Only six (28.6%) 
hospitals with PIS have the capability to generate four types of reports(ranking 
physicians by utilization, drug they prescribe, most utilized drug by number of 
patients, most utilized drug by diagnosis). ConClusions: Adopting PIS in Saudi 
hospitals is improving comparing to 2003 study, however, the integration of the 
EMR and CPOE still not to the expected level. To ptimize the institutional Pharmacy 
Benefit Management Program (PBMP), the detection and reporting capabilities of 
the PIS should be improved to facilitate prescribing decision making process, and to 
improve concurrent, prospective, and retrospective drug utilization review process.
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objeCtives: Both the HTA Core Model® (CM) for pharmaceutical evaluations and the 
Academy of Managed Care Pharmacy (AMCP) Format (Format) for formulary submis-
sions were developed to streamline health technology assessment (HTA). The CM is 
specific to European HTAs, while the Format is specific to US managed care. This study 
aims to compare these approaches to identify areas of overlap, and differing elements 
that may reflect regional values and preferences. Methods: The CM for pharmaceu-
ticals (Version 2.1) and the Format (Version 3.1) were examined and analyzed by two 
reviewers. A table of 17 characteristics was created to evaluate which elements align 
or do not align. Results: Of the 17 characteristics, 5 were found to be aligned, 5 were 
somewhat aligned, and 7 were not at all aligned. The CM provides more detailed guid-
ance (388 pages of guidance, 447 pages total) on desired data sources and rationale, 
whereas the Format provides only a short overview of requirements and methodol-
ogy (17 pages of guidance, 95 total). There is general alignment in terms of requiring 
information on burden of disease, existing treatment options, clinical effectiveness, 
and economic analyses, however within these overarching themes, certain variations 
exist. For example, the CM suggests cost-effectiveness, -utility or -benefit analyses, 
while the Format suggests only cost-effectiveness analyses. In addition, the CM con-
tains additional sections, including ethical analysis, organizational aspects, social 
aspects, and legal aspects. Alternatively, the Format contains an addendum specific to 
use of comparative effectiveness research (CER), as defined in the US, stipulating that 
CER studies reflect patient preferences. It also contains a separate addendum specific 
to specialty pharmaceuticals. ConClusions: While the CM and Format require simi-
lar information to be submitted, certain regional values and health system differences 
are reflected in the varying approaches. Trans-Atlantic collaboration could be helpful 
in standardizing characteristics across these frameworks.
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objeCtives: Biologics have made substantial contribution in a number of dis-
eases, but the high cost of therapy in the arena of cost containment impacting 
their accessibility and sustainability. Biosimilars are a viable alternative after patent 
expiry of many first generation originator biologics. Expecting a 20-30% difference 
in price from a branded product, budget impact is being considered an impor-
tant area driving the market access of these products. Hence, we reviewed the 
published budget impact analysis (BIA) of the biosimilars conducted in different 
countries’. Methods: We searched the PubMed, ISPOR, google scholar database 
etc. for English language articles with search terms “budget impact” OR “budget 
analysis” AND “biosimilar” OR “subsequent entry biological” OR “follow-on biologi-
cal”. The methodology of analysis and the major outcomes such as cost saving and 
additional patients treated were reviewed from the included studies. Results: 
Articles reporting the BIA of biosimilars were identified. The studies with BIA were 
segregated based on the countries. The source of funding, model used, and descrip-
tion provided around the model for the BIA was identified. The budget savings 
projected over 2015-2019 ranged from 95.8mn to 433mn at 10% and 30% discount, 
respectively, for UK, Italy, France, and Germany. The net benefit of 29.8mn over 3 
years period resulted in treatment of 1025 to 1615 more patients yearly. ISPOR BIA 
good practice II task force guidance was used to assess the analytical framework, 
data sources, and reporting format. ConClusions: The use of biosimilars seems 
to economically attractive, probably due to cost-savings and additional patients’ 
treatment. However, there is low availability of BIAs for biosimilars, where they 
were introduced long back and/or no availability in countries where just entered the 
market. This potential raises the need for highly robust BIAs, thus, aid in decision-
making for judicious allocation of the budget.
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objeCtives: Healthcare contributes a major proportion of public expenditures. 
The Finnish publicly funded healthcare system consists of primary and secondary 
healthcare services. Currently, specialized healthcare is responsible of 45-55% of 
total healthcare expenditures. The aim was to clarify the current and projected 
future costs for both primary and secondary healthcare. Methods: This register-
based study was performed in a selected area covering approximately 200,000 
inhabitants. The data set consists of 1,55 million healthcare contacts to primary 
or secondary healthcare during 2013. All events were matched to individuals with 
the unique national identification code, in order to obtain the per-patient costs in 
different ages. In the future cost projections, it was assumed the per-patient-costs 
